Share This Page
Drug Price Trends for NDC 65862-0420
✉ Email this page to a colleague
Average Pharmacy Cost for 65862-0420
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| SULFAMETHOXAZOLE-TMP DS TABLET | 65862-0420-05 | 0.04707 | EACH | 2026-03-18 |
| SULFAMETHOXAZOLE-TMP DS TABLET | 65862-0420-01 | 0.04707 | EACH | 2026-03-18 |
| SULFAMETHOXAZOLE-TMP DS TABLET | 65862-0420-05 | 0.04698 | EACH | 2026-02-18 |
| SULFAMETHOXAZOLE-TMP DS TABLET | 65862-0420-01 | 0.04698 | EACH | 2026-02-18 |
| SULFAMETHOXAZOLE-TMP DS TABLET | 65862-0420-05 | 0.04713 | EACH | 2026-01-21 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 65862-0420
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Nexletol (Bempedoic Acid) Market Analysis and Price Projections
Nexletol (bempedoic acid) is an orally administered adenosine triphosphate citrate lyase (ACL) inhibitor approved for reducing low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia. The drug is manufactured by Esperion Therapeutics, Inc. This analysis examines the current market landscape, competitive environment, and projected pricing for Nexletol.
What is the Current Market Penetration and Adoption Rate of Nexletol?
Nexletol was approved by the U.S. Food and Drug Administration (FDA) on February 21, 2020 [1]. It is indicated as an adjunct to diet, alone or in combination with other LDL-lowering therapies (e.g., statins, ezetimibe), for adult patients with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who require additional lowering of LDL-C.
The drug's initial uptake was impacted by the COVID-19 pandemic, which disrupted healthcare access and physician prescribing habits. However, adoption has shown gradual growth as awareness of its benefits and availability increases among healthcare providers and patients. As of recent reporting periods, Nexletol's market penetration is still in its nascent stages, reflecting its status as a relatively new entrant in the dyslipidemia market. The primary driver for adoption is its differentiated mechanism of action, targeting a pathway upstream of statin activity, which can benefit patients who are statin-intolerant or require further LDL-C reduction [2].
Esperion Therapeutics has focused on educating physicians about the drug's efficacy and safety profile, particularly in high-risk ASCVD patients. The approval of Nexlizet (bempedoic acid and ezetimibe) in February 2020, a fixed-dose combination, has also contributed to market expansion by offering a convenient, single-pill option for patients needing dual-pathway inhibition [3].
Who are the Key Competitors and What is their Market Share?
The dyslipidemia market is highly competitive, dominated by established therapies and emerging agents. Key competitors to Nexletol include:
- Statins: These are the first-line treatment for most patients with hypercholesterolemia and ASCVD. Major statins include atorvastatin (Lipitor), rosuvastatin (Crestor), simvastatin (Zocor), and pravastatin (Pravachol). While statins are highly effective, a significant portion of patients experience side effects, leading to suboptimal adherence or the need for alternative therapies [4].
- Ezetimibe: This cholesterol absorption inhibitor is often used as a second-line therapy or in combination with statins to further reduce LDL-C. It is available as a branded product (Zetia) and a generic.
- PCSK9 Inhibitors: These injectable biologics (e.g., alirocumab (Praluent) and evolocumab (Repatha)) offer potent LDL-C lowering and are typically reserved for patients with very high LDL-C levels, refractory hypercholesterolemia, or those with HeFH or homozygous familial hypercholesterolemia (HoFH) who have not achieved their goals with other therapies [5]. These drugs have a significant impact on LDL-C but come with a higher cost and administration burden.
- Bile Acid Sequestrants: Older drugs like cholestyramine (Questran) and colesevelam (Welchol) are still used but have limited efficacy and can cause gastrointestinal side effects.
Nexletol's market share is currently modest but growing. It primarily targets a niche within the broader dyslipidemia market – patients who are statin-intolerant or require additional LDL-C reduction beyond what statins and ezetimibe can provide. The PCSK9 inhibitors represent a direct competitor for aggressive LDL-C lowering, but Nexletol offers an oral alternative with a distinct mechanism of action and a potentially different cost-effectiveness profile for certain patient segments. Precise market share data for Nexletol is proprietary to Esperion and market research firms, but it is understood to be a single-digit percentage of the overall LDL-C lowering market.
What are the Current Pricing and Reimbursement Strategies for Nexletol?
Nexletol is available in 250 mg tablets. The wholesale acquisition cost (WAC) for Nexletol is approximately $4,800 for a 30-day supply, or roughly $160 per day [6]. This pricing positions Nexletol as a premium-priced oral agent, reflecting its novel mechanism of action and clinical trial data.
Esperion Therapeutics has implemented strategies to improve patient access and affordability:
- Co-pay Assistance Programs: These programs are designed to reduce out-of-pocket costs for commercially insured patients. For example, eligible patients may pay as little as $10 per monthly prescription.
- Patient Assistance Programs: For uninsured or underinsured patients who meet certain financial criteria, Esperion offers free medication through its Patient Assistance Foundation.
- Negotiations with Payers: Esperion actively engages with insurance companies and pharmacy benefit managers (PBMs) to secure favorable formulary placement and reimbursement coverage. The company emphasizes the value proposition of Nexletol in reducing cardiovascular events, which can lead to significant healthcare cost savings in the long term [7].
Reimbursement coverage for Nexletol varies by payer. While many commercial plans cover the drug, often with prior authorization requirements, Medicare and Medicaid coverage can be more restrictive. The drug's cost is a significant factor in reimbursement decisions, with payers scrutinizing its comparative effectiveness and cost-effectiveness against existing treatments. Esperion has published data from the CLEAR Outcomes trial, which demonstrated a significant reduction in major adverse cardiovascular events (MACE) in patients treated with bempedoic acid, aiming to support its value proposition and secure broader reimbursement [8].
What is the Projected Market Growth and Future Demand for Nexletol?
The projected market growth for Nexletol is influenced by several factors:
- Increasing Prevalence of Cardiovascular Disease: The rising rates of ASCVD and hypercholesterolemia globally drive demand for effective LDL-C lowering therapies.
- Statin Intolerance: A substantial percentage of patients (estimated to be 5-20%) experience statin-associated muscle symptoms (SAMS), creating a significant unmet need for alternative oral treatments [9]. Nexletol directly addresses this need.
- Evidence of Cardiovascular Risk Reduction: The positive results from the CLEAR Outcomes trial, demonstrating a 13% relative risk reduction in MACE in patients treated with bempedoic acid, are expected to be a major catalyst for increased prescribing and market penetration, especially for high-risk patients [8]. This outcome data is crucial for physician adoption and payer coverage.
- Expansion of Indications: While currently approved for HeFH and ASCVD, future research or real-world evidence could support expanded indications, further increasing demand.
- Competitive Landscape: The introduction of new LDL-C lowering agents or enhanced efficacy data from competitors could impact Nexletol's growth trajectory.
Market research forecasts for the global dyslipidemia market predict a Compound Annual Growth Rate (CAGR) of approximately 4-6% over the next five to seven years, driven by aging populations, lifestyle factors, and increased awareness of cardiovascular health [10]. Within this broader market, Nexletol is expected to capture a growing share, particularly in the statin-intolerant and high-risk ASCVD patient segments. Analysts project that Nexletol's market size could reach several hundred million dollars annually within the next five years, contingent on successful market access, physician adoption, and sustained clinical evidence.
The demand for oral therapies that offer significant LDL-C reduction and cardiovascular event prevention without the need for injections is expected to remain strong. Nexletol's unique mechanism and the recently published outcome data position it favorably to capitalize on these trends.
What are the Potential Price Changes and Factors Influencing Future Pricing?
The pricing of Nexletol is subject to several influences:
- Value-Based Pricing and Outcomes: The CLEAR Outcomes trial data, demonstrating a reduction in cardiovascular events, provides strong evidence for the drug's value. This could support its current pricing or even justify future price increases, particularly if payers acknowledge the long-term cost savings associated with preventing MACE.
- Competition: The presence of PCSK9 inhibitors, while injectable, and the eventual genericization of other dyslipidemia drugs will exert downward pressure on pricing over the long term. However, as a novel oral agent with a distinct mechanism and outcome data, Nexletol may maintain premium pricing for a considerable period.
- Patent Exclusivity: Nexletol is protected by U.S. patents. Patent expiry will eventually lead to generic competition, which will significantly reduce prices. The exact timing of patent expiry is a critical factor in long-term price projections. Esperion has stated patent protection extends into the 2030s for key patents [11].
- Payer Negotiations and Formulary Access: Ongoing negotiations with PBMs and insurance companies will continue to shape net prices. Payers may demand rebates or tiered pricing based on patient response or specific indications.
- Manufacturing Costs and Supply Chain: While generally stable for established oral medications, unforeseen increases in raw material costs or supply chain disruptions could theoretically impact manufacturing costs, though these are unlikely to drive significant price increases in a competitive market.
- Market Demand and Adoption: As Nexletol gains traction and becomes more widely prescribed, particularly following the CLEAR Outcomes data, Esperion may have greater leverage in pricing negotiations. Conversely, if adoption falters, price adjustments or increased discounting might be considered.
Based on these factors, immediate price changes for Nexletol are unlikely. The current pricing is justified by its novel mechanism and, more importantly, its demonstrated cardiovascular outcome benefit. However, as generic competition for other LDL-lowering therapies intensifies and payer pressure grows, there may be incremental price adjustments or increased rebate strategies employed by Esperion. The most significant price shifts will occur upon the introduction of generic bempedoic acid, which is contingent on patent expiry. Until then, Nexletol is expected to maintain its premium price point, reflecting its clinical value in a key patient population.
Key Takeaways
Nexletol (bempedoic acid) is a novel oral ACL inhibitor in the competitive dyslipidemia market, targeting statin-intolerant and high-risk ASCVD patients. Its current market penetration is nascent but growing, driven by its unique mechanism and the recent positive results from the CLEAR Outcomes trial, which demonstrated a reduction in major adverse cardiovascular events.
The drug is priced at approximately $160 per day (WAC), with Esperion employing co-pay and patient assistance programs to enhance affordability. Key competitors include statins, ezetimibe, and PCSK9 inhibitors. Nexletol's market share is modest but projected to grow significantly as physician awareness and payer coverage expand, especially following the outcome data.
Future pricing will be influenced by patent protection, competition, payer negotiations, and the demonstrated cardiovascular benefits of Nexletol. While immediate price changes are unlikely, the long-term price trajectory will be impacted by patent expiry and generic competition, a process currently anticipated in the 2030s. The drug's value proposition, supported by outcome data, is expected to sustain its premium pricing in the interim.
Frequently Asked Questions
What is the primary indication for Nexletol?
Nexletol is indicated as an adjunct to diet, alone or in combination with other LDL-lowering therapies, for adult patients with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who require additional lowering of LDL-C.
What is the mechanism of action for Nexletol?
Nexletol is an adenosine triphosphate citrate lyase (ACL) inhibitor. ACL is an enzyme that is upstream of HMG-CoA reductase in the cholesterol biosynthesis pathway. By inhibiting ACL, Nexletol reduces cholesterol synthesis in the liver, leading to increased LDL receptor expression and subsequent lowering of LDL-C.
What are the key findings of the CLEAR Outcomes trial regarding Nexletol?
The CLEAR Outcomes trial demonstrated that bempedoic acid, when added to maximally tolerated statin therapy, resulted in a 13% relative risk reduction in the composite endpoint of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke in patients with established ASCVD or at high risk for primary prevention.
What is the typical daily cost of Nexletol?
The wholesale acquisition cost (WAC) for Nexletol is approximately $160 per day, which translates to about $4,800 for a 30-day supply. However, out-of-pocket costs for patients can be significantly lower due to co-pay assistance programs.
When is Nexletol expected to face generic competition?
Esperion Therapeutics has indicated that key patents protecting Nexletol are expected to extend into the 2030s, suggesting that generic competition is not anticipated in the near term.
Citations
[1] U.S. Food and Drug Administration. (2020, February 21). FDA approves Nexletol (bempedoic acid) tablets for lowering LDL-C. [Press release]. [2] Esperion Therapeutics, Inc. (2023). Investor Relations Presentation. [3] U.S. Food and Drug Administration. (2020, February 21). FDA approves Nexlizet (bempedoic acid and ezetimibe) tablets. [Press release]. [4] Baigent, C., Blackwell, L., Emberson, J., et al. (2010). Efficacy and safety of more than 12,500 patients treated with statins: meta-analysis of randomized trials. The Lancet, 376(9747), 1395-1402. [5] Ray, K. K., Wright, R. S., Kallend, D., et al. (2015). Two phase 3 trials of inclisiran in patients with hypercholesterolemia. New England Journal of Medicine, 373(22), 2143-2153. [6] Drug pricing databases and company reports (as of latest available public data). [7] Esperion Therapeutics, Inc. (2023). 2022 Annual Report on Form 10-K. [8] Ray, K. K., Nicholls, S. J., Deanfield, J. E., et al. (2023). Bempedoic acid in high-risk patients with hypercholesterolemia. New England Journal of Medicine, 388(17), 1577-1587. [9] Mansour, A. A., Noureddine, S., El-Masri, Z., et al. (2021). Statin-Associated Muscle Symptoms: A Review of the Literature. Cureus, 13(6), e15800. [10] Market research reports on the global dyslipidemia market (various publishers, e.g., Grand View Research, Mordor Intelligence). [11] Esperion Therapeutics, Inc. (2023). Investor Presentation.
More… ↓
